A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on Ad Libitum energy intake in humans

Journal of Clinical Endocrinology and Metabolism

Volumn 86, Issue 9, 2001, Pages 4382-4389

  Verdich, C ^a   Flint, A ^a   Gutzwiller, J P ^d   Naslund E ^b   Beglinger, C ^d   Hellstrom P M ^e   Long, S J ^c   Morgan, L M ^c   Holst, J J ^f   Astrup, A ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b DANDERYD HOSPITAL   (Sweden)

^c UNIVERSITY OF SURREY   (United Kingdom)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; PLACEBO;

APPETITE; ARTICLE; BODY MASS; BODY WEIGHT; CALORIC INTAKE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOSE TIME EFFECT RELATION; GLUCAGON RELEASE; HUMAN; HUMAN EXPERIMENT; MALE; META ANALYSIS; NORMAL HUMAN; OBESITY; PEPTIDE ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; SATIETY; STATISTICAL ANALYSIS; STOMACH EMPTYING; WELLBEING;

ADULT; APPETITE; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; EATING; ENERGY METABOLISM; GASTRIC EMPTYING; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDES; HUMANS; HUNGER; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; MALE; OBESITY; PEPTIDE FRAGMENTS; RANDOMIZED CONTROLLED TRIALS; SATIETY RESPONSE;

EID: 17944365214     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.86.9.4382     Document Type: Article

References (25)

1. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans
2. Glucagon-like peptide 1 (GLP-1): An intestinal hormone, signalling nutritional abundance, with an unusual therapeutic potential
3. A role for glucagon-like peptide-1 in the central regulation of feeding
4. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats
5. Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men
6. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men
7. No effect of glucagon-like peptide-1 on short-term satiety and energy intake in man
8. Glucagon-like peptide-1: A potent regulator of food intake in humans
9. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2
10. The effect of glucagon-like peptide -1 on appetite, gastric emptying and substrate metabolism
11. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients
12. Normalization of fasting hyperglycaenmia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients
13. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes
14. Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37] in type 2 diabetic patients
15. The role of dietary fat in body fatness: Evidence from a preliminary meta-analysis of ad libitum low-fat dietary intervention studies
16. Gastric emptying: Comparison of scintigraphic, polyethylene glycol dilution, and paracetamol tracer assessment technique
17. Liquid gastric emptying assessed by direct and indirect tecniques: Radionucleotide labelled liquid emptying compared with a simple paracetamol marker method
18. Distal small bowel hormones: Correlation with fasting antroduodenal motility and gastric emptying
19. Attenuated GLP-1 secretion in obesity: Cause or consequence?
20. Inhibition of carbohydrate-mediated glucagon-like peptide-1 (7-36)amide secretion by circulating non-estrified fatty acids
21. The role of postprandial releases of insulin and incretin hormones in meal-induced satiety - Effect of obesity and weight reduction
22. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans
23. Glucagon-like peptide 1 and its potential in the treatment of non-insulin-dependent diabetes mellitus
24. The benefits of modest weight loss in type II diabetes
25. Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats